| Schedule of continued operations by reportable segment |
The
following tables summarize, for the periods indicated, operating results, from continued operations by reportable segment ($ in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
|
Pharmaceutical and
|
|
|
|
|
|
|
Products
|
|
Biotechnology
|
|
|
|
|
Year Ended December 31, 2019
|
|
Sales
|
|
Product Development
|
|
Consolidated
|
|
Net revenue
|
|
$
|
34,921
|
|
$
|
1,708
|
|
$
|
36,629
|
|
Direct cost of goods
|
|
|
(10,532)
|
|
|
—
|
|
|
(10,532)
|
|
Sales and marketing costs
|
|
|
(17,120)
|
|
|
—
|
|
|
(17,120)
|
|
Research and development
|
|
|
—
|
|
|
(81,326)
|
|
|
(81,326)
|
|
General and administrative
|
|
|
(2,556)
|
|
|
(35,914)
|
|
|
(38,470)
|
|
Other income
|
|
|
—
|
|
|
9,159
|
|
|
9,159
|
|
Segment gain (loss) from operations
|
|
$
|
4,713
|
|
$
|
(106,373)
|
|
$
|
(101,660)
|
|
Segment assets
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net
|
|
$
|
7,377
|
|
$
|
—
|
|
$
|
7,377
|
|
Tangible assets
|
|
|
19,946
|
|
|
199,099
|
|
|
219,045
|
|
Total segment assets
|
|
$
|
27,323
|
|
$
|
199,099
|
|
$
|
226,422
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
|
Pharmaceutical and
|
|
|
|
|
|
|
Products
|
|
Biotechnology
|
|
|
|
|
Year Ended December 31, 2018
|
|
Sales
|
|
Product Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
23,376
|
|
$
|
3,506
|
|
$
|
26,882
|
|
Direct cost of goods
|
|
|
(6,125)
|
|
|
—
|
|
|
(6,125)
|
|
Sales and marketing costs
|
|
|
(11,639)
|
|
|
—
|
|
|
(11,639)
|
|
Research and development
|
|
|
—
|
|
|
(87,383)
|
|
|
(87,383)
|
|
General and administrative
|
|
|
(1,778)
|
|
|
(39,954)
|
|
|
(41,732)
|
|
Other expense
|
|
|
|
|
|
(10,803)
|
|
|
(10,803)
|
|
Segment gain (loss) from operations
|
|
$
|
3,834
|
|
$
|
(134,634)
|
|
$
|
(130,800)
|
|
Segment assets
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net
|
|
$
|
1,417
|
|
$
|
—
|
|
$
|
1,417
|
|
Tangible assets
|
|
|
8,984
|
|
|
130,592
|
|
|
139,576
|
|
Total segment assets
|
|
$
|
10,401
|
|
$
|
130,592
|
|
$
|
140,993
|
|